Histology-Specific Therapy for Advanced Soft Tissue Sarcoma and Benign Connective Tissue Tumors
- 395 Downloads
Molecularly targeted agents have shown activity in soft tissue sarcoma (STS) and benign connective tissue tumors over the past ten years, but response rates differ by histologic subtype. The field of molecularly targeted agents in sarcoma is increasingly complex. Often, clinicians must rely on phase II data or even case series due to the rarity of these diseases. In subtypes with a clear role of specific factors in the pathophysiology of disease, such as giant cell tumor of the bone and diffuse-type tenosynovial giant cell tumor, it is reasonable to treat with newer targeted therapies, when available, in place of chemotherapy when systemic treatment is needed to control disease. In diseases without documented implication of a pathway in disease pathogenesis (e.g. soft tissue sarcoma and vascular endothelial growth factor), clear benefit from drug treatment should be established in randomized phase III trials before implementation into routine clinical practice. Histologic subtype will continue to emerge as a critical factor in treatment selection as we learn more about the molecular drivers of tumor growth and survival in different subtypes. Many of the drugs that have been recently developed affect tumor growth more than survival, therefore progression-free survival may be a more clinically relevant intermediate endpoint than objective response rate using Response Evaluation Criteria In Solid Tumors (RECIST) in early phase sarcoma trials. Because of the rarity of disease and increasing need for multidisciplinary management, patients with connective tissue tumors should be evaluated at a center with expertise in these diseases. Participation in clinical trials, when available, is highly encouraged.
KeywordsSarcoma Connective tissue tumor Inflammatory myofibroblastic tumor Tyrosine kinase inhibitor Pazopanib mTOR inhibitor PEComa Giant cell tumor
A.W. Silk: none; S.M. Schuetze: Consultant to GlaxoSmithKline, payment for manuscript preparation and speakers’ bureau for Novartis.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755–63.PubMedCrossRefGoogle Scholar
- 4.•Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–1779. Analysis of patients with advanced dermatofibrosarcoma protuberans treated with imatinib suggesting that a dose of 400 mg daily is as effective and better tolerated than 400 mg twice daily.Google Scholar
- 5.•Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012;118:1649–1655. Series documenting activity of imatinib in managing patients with recurrent or unresectable diffuse-type tenosynovial giant cell tumor.Google Scholar
- 8.Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 2012;17(2):260–6.Google Scholar
- 12.•Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol. 2009;27:3126–3132. Pazopanib was well-tolerated and had clinical activity in patients with advanced leiomyosarcomas, synovial sarcomas, and other STS types, but not adipocytic sarcomas.Google Scholar
- 13.••Van Der Graaf WT, Blay J, Chawla SP, et al. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). Abstract presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; June 3–7, 2011. Abstract LBA10002. The PALETTE study showed that pazopanib significantly improved PFS (median: 20 vs 7 weeks; HR = 0.31, 95 % CI 0.24-0.40 ; P < 0.0001).Google Scholar
- 15.•Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22:1682–1690. One of the first trials to demonstrate a significant objective response rate in alveolar soft part sarcoma treated with a drug.Google Scholar
- 17.NCCN Guidelines, version 1. Soft Tissue Sarcoma. 2012. Available at: http://www.nccn.org/index.asp. Accessed March 18, 2012.
- 18.Gardner K, Judson I, Leahy M, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. Abstract presented at the 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL; May 29–June 2, 2009. Abstract 10523.Google Scholar
- 19.Kummar S, Strassberger A, Monks A, et al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). Abstract presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; June 3–7, 2011. Abstract 10001.Google Scholar
- 20.US National Institutes of Health Clinical Trials: Sunitinib or cediranib for alveolar soft part sarcoma. 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01391962. Accessed March 3, 2012.
- 22.•Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012, 30:78–84. In this relatively large study of patients with unresectable or metastatic sarcoma, 29 % had stable disease or partial response at 16 weeks, but the objective response rate was less than 5 %.Google Scholar
- 23.Chawla SP, Blay J, Ray-Coquard IL, et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Abstract presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; June 3–7, 2011. Abstract 10005.Google Scholar
- 25.Italiano A, Kind Ml, Stoeckle E, Jones N, Coindre J-M, Bui B. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. Anticancer Drugs. 2011;22:463–467.Google Scholar
- 28.•Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28:835–840. Small series demonstrating that malignant PEComa may respond to treatment with mTOR inhibitor.Google Scholar
- 35.Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2012;23(2):501–8.Google Scholar
- 42.••Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:1727–1733. This case report of two patients led to the recent update to the NCCN guidelines to include crizotinib as an option for management of patients with ALK + IMT.Google Scholar
- 43.••Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. The Lancet Oncology 2010;11:275–280. Phase II study demonstrating significant activity of denosumab, a monoclonal antibody to RANK ligand, in the management of patients with locally advanced or metastatic giant cell tumor of bone.Google Scholar